RASAL1 alterations cause constitutive activation of RAS, initiating the PI3K pathway signaling, which will be unconstrained in the presence of defective PTEN, thus constantly activating the PI3K pathway signaling and driving the aggressiveness and poor clinical outcomes of human cancer (Fig. 4G). This evidence concerns the gene RASAL1 and cancer.